The Structural Biology of Ubiquitin-Protein Ligases

Protein Degradation

Volumn 1, Issue , 2007, Pages 156-189

  Zheng, Ning ^a   Pavletich, Nikola P ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

C Cbl UbcH7 complex; E3 function; E6AP HECT domain in complex with UbcH7; Mms2 Ubc13 complex; Protein degradation; RanGAP1 Ubc9 complex; SCF E3 superfamily; Structural biology; Ubiquitin protein ligases

Indexed keywords

EID: 33845467464     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619320.ch7     Document Type: Chapter

References (109)

1. Hershko, A. and Ciechanover, A. The ubiquitin system. Annu Rev Biochem 1998, 67, 425-79.
2. Hicke, L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001, 2, 195-201.
3. Pickart, C. M. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70, 503-33.
4. Ciechanover, A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 2003, 31, 474-81.
5. Hershko, A., Heller, H., Elias, S. and Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983, 258, 8206-14.
6. Joazeiro, C. A. and Weissman, A. M. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000, 102, 549-52.
7. Scheffner, M., Nuber, U. and Huibregtse, J. M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 1995, 373, 81-3.
8. Jackson, P. K. et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000, 10, 429-39.
9. Cyr, D. M., Hohfeld, J. and Patterson, C. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci 2002, 27, 368-75.
10. Haas, A. L. and Siepmann, T. J. Pathways of ubiquitin conjugation. Faseb J 1997, 11, 1257-68.
11. Scheffzek, K., Ahmadian, M. R. and Wittinghofer, A. GTPase-activating proteins: helping hands to complement an active site. Trends Biochem Sci 1998, 23, 257-62.
12. Joazeiro, C. A. et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286, 309-12.
13. Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999, 96, 11364-9.
14. Wu, P. Y. et al. A conserved catalytic residue in the ubiquitin-conjugating enzyme family. Embo J 2003, 22, 5241-50.
15. Kornitzer, D., Raboy, B., Kulka, R. G. and Fink, G. R. Regulated degradation of the transcription factor Gcn4. Embo J 1994, 13, 6021-30.
16. Treier, M., Staszewski, L. M. and Bohmann, D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994, 78, 787-98.
17. Chau, V. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989, 243, 1576-83.
18. Baldi, L., Brown, K., Franzoso, G. and Siebenlist, U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J Biol Chem 1996, 271, 376-9.
19. Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T. and Ballard, D. W. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 1995, 92, 11259-63.
20. Wilkinson, K. D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000, 11, 141-8.
21. Freiman, R. N. and Tjian, R. Regulating the regulators: lysine modifications make their mark. Cell 2003, 112, 11-7.
22. Desterro, J. M., Rodriguez, M. S. and Hay, R. T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 1998, 2, 233-9.
23. Li, M., Luo, J., Brooks, C. L. and Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002, 277, 50607-11.
24. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A. and Kouzarides, T. Regulation of E2F1 activity by acetylation. Embo J 2000, 19, 662-71.
25. Di Fiore, P. P., Polo, S. and Hofmann, K. When ubiquitin meets ubiquitin receptors: a signalling connection. Nat Rev Mol Cell Biol 2003, 4, 491-7.
26. Sancho, E. et al. Role of UEV-1, an inactive variant of the E2 ubiquitinconjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol Cell Biol 1998, 18, 576-89.
27. Hofmann, R. M. and Pickart, C. M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1999, 96, 645-53.
28. Cook, W. J., Jeffrey, L. C., Sullivan, M. L. and Vierstra, R. D. Threedimensional structure of a ubiquitinconjugating enzyme (E2). J Biol Chem 1992, 267, 15116-21.
29. Saurin, A. J., Borden, K. L., Boddy, M. N. and Freemont, P. S. Does this have a familiar RING? Trends Biochem Sci 1996, 21, 208-14.
30. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63, 1129-36.
31. Huibregtse, J. M., Scheffner, M. and Howley, P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. Embo J 1991, 10, 4129-35.
32. Jiang, Y., Lev-Lehman, E., Bressler, J., Tsai, T. F. and Beaudet, A. L. Genetics of Angelman syndrome. Am J Hum Genet 1999, 65, 1-6.
33. Schwarz, S. E., Rosa, J. L. and Scheffner, M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 1998, 273, 12148-54.
34. Wang, G., Yang, J. and Huibregtse, J. M. Functional domains of the Rsp5 ubiquitin-protein ligase. Mol Cell Biol 1999, 19, 342-52.
35. Scheffner, M., Huibregtse, J. M. and Howley, P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 1994, 91, 8797-801.
36. Nuber, U., Schwarz, S., Kaiser, P., Schneider, R. and Scheffner, M. Cloning of human ubiquitinconjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. J Biol Chem 1996, 271, 2795-800.
37. Kumar, S., Kao, W. H. and Howley, P. M. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J Biol Chem 1997, 272, 13548-54.
38. Huang, L. et al. Structure of an E6APUbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999, 286, 1321-6.
39. Verdecia, M. A. et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol Cell 2003, 11, 249-59.
40. Thien, C. B. and Langdon, W. Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2, 294-307.
41. Haglund, K., Di Fiore, P. P. and Dikic, I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 2003, 28, 598-603.
42. Mosesson, Y. et al. Endocytsosis of receptor tyrosine kinases is driven by mono-, not poly-ubiquitylation. J Biol Chem 2003.
43. Petrelli, A. et al. The endophilin-CIN85-Cbl complex mediates liganddependent downregulation of c-Met. Nature 2002, 416, 187-90.
44. Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y. and Dikic, I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002, 416, 183-7.
45. Haglund, K. et al. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003, 5, 461-6.
46. Thien, C. B. and Langdon, W.Y. C-Cbl: a regulator of T cell receptormediated signalling. Immunol Cell Biol 1998, 76, 473-82.
47. Levkowitz, G. et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4, 1029-40.
48. Meng, W., Sawasdikosol, S., Burakoff, S. J. and Eck, M. J. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 1999, 398, 84-90.
49. Zheng, N., Wang, P., Jeffrey, P. D. and Pavletich, N. P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000, 102, 533-9.
50. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999, 15, 435-67.
51. Zachariae, W. et al. Mass spectrometric analysis of the anaphasepromoting complex from yeast: identification of a subunit related to cullins. Science 1998, 279, 1216-9.
52. Yu, H. et al. Identification of a cullin homology region in a subunit of the anaphase-promoting complex. Science 1998, 279, 1219-22.
53. Ohta, T., Michel, J. J., Schottelius, A. J. and Xiong, Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999, 3, 535-41.
54. Dias, D. C., Dolios, G., Wang, R. and Pan, Z. Q. CUL7: A DOC domaincontaining cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc Natl Acad Sci USA 2002, 99, 16601-6.
55. Pintard, L. et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 2003, 425, 311-6.
56. Xu, L. et al. BTB proteins are substrate-specific adaptors in an SCFlike modular ubiquitin ligase containing CUL-3. Nature 2003, 425, 316-21.
57. Kipreos, E. T. and Pagano, M. The Fbox protein family. Genome Biol 2000, 1, REVIEWS3002.
58. Winston, J. T., Koepp, D. M., Zhu, C., Elledge, S. J. and Harper, J. W. A family of mammalian F-box proteins. Curr Biol 1999, 9, 1180-2.
59. Bai, C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996, 86, 263-74.
60. Schulman, B. A. et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 2000, 408, 381-6.
61. Ganoth, D. et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001, 3, 321-4.
62. Spruck, C. et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 2001, 7, 639-50.
63. Koepp, D. M. et al. Phosphorylationdependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001, 294, 173-7.
64. Moberg, K. H., Bell, D. W., Wahrer, D. C., Haber, D. A. and Hariharan, I. K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001, 413, 311-6.
65. Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413, 316-22.
66. Wu, G. et al. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 2003, 11, 1445-56.
67. Stebbins, C. E., Kaelin, W. G., Jr. and Pavletich, N. P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284, 455-61.
68. Kile, B. T. et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002, 27, 235-41.
69. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292, 464-8.
70. Rui, L., Yuan, M., Frantz, D., Shoelson, S. and White, M. F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277, 42394-8.
71. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260, 1317-20.
72. Duan, D. R. et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995, 269, 1402-6.
73. Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997, 94, 2156-61.
74. Lonergan, K. M. et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998, 18, 732-41.
75. Ivan, M. and Kaelin, W. G., Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001, 11, 27-34.
76. Jaakkola, P. et al. Targeting of HIFalpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468-72.
77. Bruick, R. K. and McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294, 1337-40.
78. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107, 43-54.
79. Min, J. H. et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002, 296, 1886-9.
80. Nakayama, K. I., Hatakeyama, S. and Nakayama, K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001, 282, 853-60.
81. Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001, 98, 5043-8.
82. Tedesco, D., Lukas, J. and Reed, S. I. The pRb-related protein p130 is regulated by phosphorylationdependent proteolysis via the proteinubiquitin ligase SCF(Skp2). Genes Dev 2002, 16, 2946-57.
83. Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E. and Tansey, W. P. Skp2 regulates Myc protein stability and activity. Mol Cell 2003, 11, 1177-88.
84. von der Lehr, N. et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003, 11, 1189-200.
85. Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F-boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416, 703-9.
86. Groisman, R. et al. The Ubiquitin Ligase Activity in the DDB2 and CSA Complexes Is Differentially Regulated by the COP9 Signalosome in Response to DNA Damage. Cell 2003, 113, 357-67.
87. Hori, T. et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 1999, 18, 6829-34.
88. Dharmasiri, S., Dharmasiri, N., Hellmann, H. and Estelle, M. The RUB/Nedd8 conjugation pathway is required for early development in Arabidopsis. Embo J 2003, 22, 1762-70.
89. Kurz, T. et al. Cytoskeletal regulation by the Nedd8 ubiquitin-like protein modification pathway. Science 2002, 295, 1294-8.
90. Osaka, F. et al. Covalent modifier NEDD8 is essential for SCF ubiquitinligase in fission yeast. Embo J 2000, 19, 3475-84.
91. Tateishi, K., Omata, M., Tanaka, K. and Chiba, T. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol 2001, 155, 571-9.
92. Read, M. A. et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of Ikappa-Balpha. Mol Cell Biol 2000, 20, 2326-33.
93. Wu, K., Chen, A. and Pan, Z. Q. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem 2000, 275, 32317-24.
94. Morimoto, M., Nishida, T., Honda, R. and Yasuda, H. Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1). Biochem Biophys Res Commun 2000, 270, 1093-6.
95. Zheng, J. et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 2002, 10, 1519-26.
96. Liu, J., Furukawa, M., Matsumoto, T. and Xiong, Y. NEDD8 modification of CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol Cell 2002, 10, 1511-8.
97. Hart, M. et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999, 9, 207-10.
98. Li, Q. and Verma, I. M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2, 725-34.
99. Polakis, P. Wnt signaling and cancer. Genes Dev 2000, 14, 1837-51.
100. Polakis, P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999, 9, 15-21.
101. Chen, Z. et al. Signal-induced sitespecific phosphorylation targets I kappa B alpha to the ubiquitinproteasome pathway. Genes Dev 1995, 9, 1586-97.
102. Feldman, R. M., Correll, C. C., Kaplan, K. B. and Deshaies, R. J. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 1997, 91, 221-30.
103. Orlicky, S., Tang, X., Willems, A., Tyers, M. and Sicheri, F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 2003, 112, 243-56.
104. Huber, A. H., Nelson, W. J. and Weis, W. I. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 1997, 90, 871-82.
105. Haas, E., Wilchek, M., Katchalski-Katzir, E. and Steinberg, I. Z. Distribution of end-to-end distances of oligopeptides in solution as estimated by energy transfer. Proc Natl Acad Sci USA 1975, 72, 1807-11.
106. VanDemark, A. P., Hofmann, R. M., Tsui, C., Pickart, C. M. and Wolberger, C. Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell 2001, 105, 711-20.
107. Miura, T., Klaus, W., Gsell, B., Miyamoto, C. and Senn, H. Characterization of the binding interface between ubiquitin and class I human ubiquitin-conjugating enzyme 2b by multidimensional heteronuclear NMR spectroscopy in solution. J Mol Biol 1999, 290, 213-28.
108. Muller, S., Hoege, C., Pyrowolakis, G. and Jentsch, S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001, 2, 202-10.
109. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J. and Lima, C. D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitinconjugating enzyme Ubc9 and RanGAP1. Cell 2002, 108, 345-56.